Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.28−0.22 (-2.37%)
Close on Nov 17, 2026Market cap $596.89MP/E –Yield –
Cullinan Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Cullinan Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$165.46M. For fiscal 2025 it was -$175.75M. The highest annual figure on record is -$29.77M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$175.75M | – |
| FY2024 | Dec 31, 2024 | -$145.30M | – |
| FY2023 | Dec 31, 2023 | -$134.28M | – |
| FY2022 | Dec 31, 2022 | -$126.66M | – |
| FY2021 | Dec 31, 2021 | -$43.43M | – |
| FY2020 | Dec 31, 2020 | -$29.77M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$43.08M | – |
| Q2 FY2026 | Jun 30, 2026 | -$38.22M | – |
| Q1 FY2026 | Mar 31, 2026 | -$46.05M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.11M | – |
| Q3 FY2025 | Sep 30, 2025 | -$36.88M | – |
| Q2 FY2025 | Jun 30, 2025 | -$57.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$43.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.14M | – |
| Q2 FY2024 | Jun 30, 2024 | -$36.29M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.13M | – |
| Q3 FY2023 | Sep 30, 2023 | -$34.14M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$51.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$24.98M | – |
| Q3 FY2022 | Sep 30, 2022 | -$54.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.17M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.55M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.52M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.44M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.07M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.25M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.02M | – |
See a number that looks wrong?